TACR1 and colorectal carcinoma: To characterize the functional role of NK‐1R in CRC, we assessed the viability of CRC cells after treatment with the NK‐1R antagonist SR140333 and aprepitant.[11] Both antagonists potently inhibited cell proliferation in five human CRC cell lines in a dose‐ and time‐dependent manner (Figure 1F and Appendix A1 and Figure S1, Supporting Information).